Fig. 3From: A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysisPosterior Emax Dose-Response Curve for Hemoglobin (g/dL) Change from Baseline at Day 29 (ITT Population). The two dotted lines are 95% credible bands. Emax, maximal response; Hgb, hemoglobin; ITT, intention-to-treatBack to article page